LOW-DOSE SHORT-TERM CYCLOSPORINE VERSUS ETRETINATE IN PSORIASIS - IMPROVEMENT OF SKIN, NAIL, AND JOINT INVOLVEMENT

被引：112

作者：

MAHRLE, G ^{[1
]}

SCHULZE, HJ ^{[1
]}

FARBER, L ^{[1
]}

WEIDINGER, G ^{[1
]}

STEIGLEDER, GK ^{[1
]}

HUMS ^{[1
]}

PRIFERT ^{[1
]}

ALBRECHT ^{[1
]}

BORCHERS ^{[1
]}

KREYSEL ^{[1
]}

LINDENBLATT ^{[1
]}

VOGEL ^{[1
]}

KOSCHINSKI ^{[1
]}

HAGEDORN ^{[1
]}

SATTLER ^{[1
]}

GORING ^{[1
]}

PANZNER ^{[1
]}

SCHUBERT ^{[1
]}

LINDNER ^{[1
]}

TAUBE ^{[1
]}

FIEDLER ^{[1
]}

PETZOLDT ^{[1
]}

TILGEN ^{[1
]}

BAHMER ^{[1
]}

WACKER ^{[1
]}

KNOPF ^{[1
]}

BARTA ^{[1
]}

ROTH ^{[1
]}

HAUSTEIN ^{[1
]}

BIELLA ^{[1
]}

WOLFF ^{[1
]}

QUAST ^{[1
]}

SCHLENZKA ^{[1
]}

ARENSMEIER ^{[1
]}

PESCHLOW ^{[1
]}

KNOP ^{[1
]}

SCHOPF ^{[1
]}

JUNG ^{[1
]}

BAYERL ^{[1
]}

KOLDE ^{[1
]}

WESTPHAL ^{[1
]}

WURDEL ^{[1
]}

NITZSCHNER ^{[1
]}

ETTELT ^{[1
]}

机构：

[1] SANDOZ AG,DEPT CLIN RES,NURNBERG,GERMANY

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1995年 / 32卷 / 01期

关键词：

D O I：

10.1016/0190-9622(95)90189-2

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: High-dose cyclosporine therapy significantly alleviates psoriasis within 2 to 4 weeks but is associated with a high rate of side effects. Reports are conflicting on the frequency and promptness of relapse after discontinuation of cyclosporine therapy. Objective: Our purpose was to compare the efficacy and safety of low-dose cyclosporine with that of etretinate and the stability of remission after replacing cyclosporine therapy with topical anthralin during tapering of cyclosporine. Methods: In a multicenter study 210 patients with moderate to severe chronic plaque-type psoriasis were randomly assigned to treatment with cyclosporine or etretinate. The initial dosages were 2.5 mg/kg/day for cyclosporine and 0.5 mg/kg/day for etretinate, which could be individually adjusted to 5.0 and 0.75 mg/kg/day, respectively. After a treatment phase of 10 weeks (phase 1) patients receiving cyclosporine were again randomly assigned to a group in which cyclosporine was replaced by topical dithranol (anthralin), or to another group in which the drug was tapered during the next 12 weeks (phase 2). All patients treated with etretinate discontinued therapy after 10 weeks and used topical dithranol. Results: Mean Psoriasis Area and Severity Index decreased by 71% in the cyclosporine group and by 47% in the etretinate group during phase 1. After 10 weeks of treatment 47% of the patients treated with cyclosporine and 10% of those treated with etretinate showed a reduction of more than 80% in skin involvement. Sixty-four percent of the cyclosporine group and 48% of the etretinate group did not require an increase in the initial dosage, resulting in a mean daily dose of 3.0 and 0.53 mg/kg, respectively. There was significant alleviation of nail involvement and joint complaints in both groups. In phase 2 the increase in mean Psoriasis Area and Severity Index and the incidence of relapse were significantly higher in patients in whom cyclosporine was discontinued and replaced by dithranol than in patients in whom cyclosporine was tapered or who were pretreated with etretinate. During treatment four patients from the cyclosporine group and three patients of the etretinate group discontinued the study because of side effects. Conclusion: Low-dose short-term cyclosporine therapy for psoriasis is, in comparison with etretinate, highly effective and well tolerated. Individually adjusted cyclosporine therapy allows the majority of patients to continue the low dosage of 2.5 mg/kg/day and still achieve a good clinical response. Remission can be better preserved by tapering the drug than by discontinuing treatment abruptly.

引用

页码：78 / 88

页数：11

共 50 条

[21] SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI
BAZZOLI, F
ZAGARI, RM
FOSSI, S
POZZATO, P
ALAMPI, G
SIMONI, P
SOTTILI, S
RODA, A
RODA, E
[J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) : 773 - 777
[22] SHORT-TERM THERAPY OF ATHEROSCLEROSIS WITH LOW-DOSE INDOMETHACIN - AN EXPERIMENTAL-STUDY
DHAWAN, V
GANGULY, NK
MAJUMDAR, S
CHAKRAVARTI, RN
[J]. JOURNAL OF MEDICAL PRIMATOLOGY, 1990, 19 (07) : 663 - 673
[23] Short-term low-dose propofol anaesthesia associated with severe metabolic acidosis
Chukwuemeka, A.
Ko, R.
Ralph-Edwards, A.
[J]. ANAESTHESIA AND INTENSIVE CARE, 2006, 34 (05) : 651 - 655
[24] Thrombophylaxis with low-dose, short-term fondaparinux after elective hip surgery
Tsuda, Kosuke
Nishii, Takashi
Sakai, Takashi
Takao, Masaki
Nakamura, Nobuo
Sugano, Nobuhiko
[J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (03) : 413 - 421
[25] EFFECT OF SHORT-TERM, LOW-DOSE CORTICOSTEROIDS ON PLASMA-LIPOPROTEIN LIPIDS
ETTINGER, WH
KLINEFELTER, HF
KWITEROVITCH, PO
[J]. ATHEROSCLEROSIS, 1987, 63 (2-3) : 167 - 172
[26] Tardive dystonias induced by very short-term therapy with low-dose neuroleptics
Lohmann, T
Ebel, H
Ferbert, A
Sass, H
[J]. NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH, 1995, 3 (03) : 189 - 192
[27] Manic symptoms probably associated with short-term low-dose quetiapine use
Erberk-Ozen, Nurper
[J]. ADVANCES IN THERAPY, 2008, 25 (01) : 53 - 57
[28] Short-Term Safety of Paroxetine Plus Low-Dose Mirtazapine During Lactation
Uguz, Faruk
[J]. BREASTFEEDING MEDICINE, 2019, 14 (02) : 131 - 132
[29] Thrombophylaxis with low-dose, short-term fondaparinux after elective hip surgery
Kosuke Tsuda
Takashi Nishii
Takashi Sakai
Masaki Takao
Nobuo Nakamura
Nobuhiko Sugano
[J]. Journal of Thrombosis and Thrombolysis, 2016, 41 : 413 - 421
[30] Effect of short-term, low-dose treatment with tamoxifen in patients with primary dysmenorrhea
Pierzynski, Piotr
Swiatecka, Jolanta
Oczeretko, Edward
Laudanski, Piotr
Batra, Satish
Laudanski, Tadeusz
[J]. GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (12) : 698 - 703

← 1 2 3 4 5 →